EXACT Sciences Company Insiders
| EXAS Stock | USD 102.26 0.11 0.11% |
EXACT Sciences employs about 6.9 K people. The company is managed by 28 executives with a total tenure of roughly 37 years, averaging almost 1.0 years of service per executive, having 246.43 employees per reported executive. Breaking down EXACT Sciences' management performance can provide insight into the firm performance.
| Kevin Conroy Chairman Chairman of The Board, CEO and Pres |
EXACT Sciences' latest congressional trading
Congressional trading in companies like EXACT Sciences, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in EXACT Sciences by those in governmental positions are based on the same information available to the general public.
| 2020-11-20 | Representative Jim Hagedorn | Acquired Under $15K | Verify |
EXACT Sciences Management Team Effectiveness
The company has return on total asset (ROA) of (0.0109) % which means that it has lost $0.0109 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3454) %, meaning that it created substantial loss on money invested by shareholders. EXACT Sciences' management efficiency ratios could be used to measure how well EXACT Sciences manages its routine affairs as well as how well it operates its assets and liabilities.EXACT Sciences secures a total of 189.92 Million outstanding shares. The majority of EXACT Sciences outstanding shares are owned by institutions. These other corporate entities are usually referred to as non-private investors looking to obtain positions in EXACT Sciences to benefit from reduced commissions. Thus, outside corporations are subject to a different set of regulations than regular investors in EXACT Sciences. Please pay attention to any change in the institutional holdings of EXACT Sciences as this could imply that something significant has changed or is about to change at the company. On November 20, 2020, Representative Jim Hagedorn of US Congress acquired under $15k worth of EXACT Sciences's common stock.
Some institutional investors establish a significant position in stocks such as EXACT Sciences in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of EXACT Sciences, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
EXACT Sciences Workforce Comparison
EXACT Sciences is rated # 4 in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 98,672. EXACT Sciences holds roughly 6,900 in number of employees claiming about 7% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.32) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. EXACT Sciences Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific EXACT Sciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on EXACT Sciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, EXACT Sciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Brian Baranick over a month ago Disposition of 14938 shares by Brian Baranick of EXACT Sciences at 101.59 subject to Rule 16b-3 | ||
Brian Baranick over a month ago Acquisition by Brian Baranick of 4725 shares of EXACT Sciences subject to Rule 16b-3 | ||
James Herriott over three months ago Disposition of 1890 shares by James Herriott of EXACT Sciences subject to Rule 16b-3 | ||
James Herriott over six months ago Disposition of 865 shares by James Herriott of EXACT Sciences subject to Rule 16b-3 | ||
Zanotti Katherine S over six months ago Disposition of 3207 shares by Zanotti Katherine S of EXACT Sciences at 53.2 subject to Rule 16b-3 | ||
James Herriott over six months ago Acquisition by James Herriott of 7334 shares of EXACT Sciences subject to Rule 16b-3 | ||
James Herriott over six months ago Acquisition by James Herriott of 363 shares of EXACT Sciences at 38.26 subject to Rule 16b-3 | ||
Kevin Conroy over six months ago Disposition of 66723 shares by Kevin Conroy of EXACT Sciences at 22.38 subject to Rule 16b-3 |
EXACT Sciences Notable Stakeholders
An EXACT Sciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as EXACT Sciences often face trade-offs trying to please all of them. EXACT Sciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting EXACT Sciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Kevin Conroy | Chairman of The Board, CEO and Pres | Profile | |
| Nicole Maassen | Market President | Profile | |
| Kevin JD | President Board | Profile | |
| Scott Coward | Sr. VP and General Counsel | Profile | |
| Graham Lidgard | Chief Science Officer and Sr. VP | Profile | |
| James Herriott | General VP | Profile | |
| Wayne Taylor | Head VP | Profile | |
| Ana Hooker | Chief Officer | Profile | |
| Aaron Bloomer | Executive Finance | Profile | |
| Vic Parker | Head Sales | Profile | |
| Sri Kalluri | Chief Officer | Profile | |
| Nassar Nizami | Chief Officer | Profile | |
| Jake MBA | Executive Screening | Profile | |
| Jorge Garces | Chief Officer | Profile | |
| Jeffrey CFA | Chief Officer | Profile | |
| Erik Holznecht | Senior Associate | Profile | |
| Derek Leckow | Vice Relations | Profile | |
| Jacob MBA | Executive Screening | Profile | |
| Steven Bellamy | Chief Region | Profile | |
| Sarah Condella | Executive Resources | Profile | |
| Tim Caprez | Chief VP | Profile | |
| Brian Baranick | Executive Oncology | Profile | |
| Vamsi Pudipeddi | Chief Officer | Profile | |
| Everett Cunningham | Chief Officer | Profile | |
| Frederick MD | Chief Oncology | Profile | |
| MD FACP | Chief Detection | Profile | |
| Megan Jones | Associate Relations | Profile | |
| MPH MD | Chief Screening | Profile |
About EXACT Sciences Management Performance
The success or failure of an entity such as EXACT Sciences often depends on how effective the management is. EXACT Sciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of EXACT management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the EXACT management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin. Exact Sciences operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 6420 people.
Please note, the imprecision that can be found in EXACT Sciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of EXACT Sciences. Check EXACT Sciences' Beneish M Score to see the likelihood of EXACT Sciences' management manipulating its earnings.
EXACT Sciences Workforce Analysis
Traditionally, organizations such as EXACT Sciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare EXACT Sciences within its industry.EXACT Sciences Manpower Efficiency
Return on EXACT Sciences Manpower
| Revenue Per Employee | 399.8K | |
| Revenue Per Executive | 98.5M | |
| Net Loss Per Employee | 149.1K | |
| Net Loss Per Executive | 36.7M | |
| Working Capital Per Employee | 121.6K | |
| Working Capital Per Executive | 30M |
Additional Tools for EXACT Stock Analysis
When running EXACT Sciences' price analysis, check to measure EXACT Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy EXACT Sciences is operating at the current time. Most of EXACT Sciences' value examination focuses on studying past and present price action to predict the probability of EXACT Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move EXACT Sciences' price. Additionally, you may evaluate how the addition of EXACT Sciences to your portfolios can decrease your overall portfolio volatility.